EUVIMEDEUVIMED entdecken
Crossref

Impact of HIV subtype on response and resistance in antiretroviral-naïve adults comparing treatment with once daily versus twice daily ritonavir boosted fosamprenavir in combination with Abacavir/Lamivudine

Lisa L. Ross, Marjorie D. Robinson, Giampiero Carosi, Adriano Lazzarin, Hans-Juergen Stellbrink, Graeme Moyle, Naomi Givens, William G. Nichols

Drugs and Therapy Studies · 2011

DOI: 10.4081/dts.2012.e1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs and Therapy Studies, 2011. Verfasst von Lisa L. Ross und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The impact of HIV-1 subtype on resistance mutation selection and on virologic response to fosamprenavir in combination with once-daily (QD) versus twice-daily (BID) dosing of ritonavir was examined in a prospective, open label, randomized study in antiretroviral-naïve, HIV-1 infected subjects. We studied APV109141 compared QD fosamprenavir/ritonavir (1400mg/100mg) to BID fosamprenavir/ritonavir (700mg/100mg), administered in combination with a QD fixed-dose abacavir/lamivudine (600 mg/300 mg) combination tablet through 48 weeks in ART-naïve subjects. HIV genotypes were obtained from all subjects at screen. Subjects with virologic failure (VF) were also genotyped at baseline and VF. HIV subtypes observed in the ITT (n=214) population were A or AE or AG circulating recombinant forms (CRFs) 19%; B 62%; BF or BG CRFs 2%; C or CPX CRFs 7%; D 2%; F1 7%; G <1%. By TLOVR (ITT-exposed), 86/106 (81%) of subjects on QD study arm and 87/106 (82%) in the BID arm achieved plasma HIV-RNA<400 copies/mL at Week 48. Three subjects met VF criteria, 2 receiving QD fosamprenavir/ritonavir; 1 receiving BID fosamprenavir/ritonavir; (HIV subtype B, F1 A1, respectively). Baseline drug resistance was detected in 2/3 VFs: Subject 1-RT: K103K/N, T215C; major PI: V82A, L90M; and Subject 2-RT: M41L, L74V. Only virus from one subject with VF selected for any treatment-emergent mutation (Subject 1; M184V). Post-VF, Subject 3 (subtypeA1) suppressed HIV-RNA >400 copies/mL through 48 weeks. Subtype appeared to have no preferential impact on virologic response or selection for specific resistance mutations in subjects receiving fosamprenavir/ritonavir. Virologic failure rate was rare (3 subjects; each from different subtypes). At VF, virus from only one subject selected any HIV NRTI mutation (M184V); none selected major protease mutations.

Zitieren

APA

Ross, L. L., Robinson, M. D., Carosi, G., Lazzarin, A., Stellbrink, H., Moyle, G., Givens, N., & Nichols, W. G. (2011). Impact of HIV subtype on response and resistance in antiretroviral-naïve adults comparing treatment with once daily versus twice daily ritonavir boosted fosamprenavir in combination with Abacavir/Lamivudine. Drugs and Therapy Studies. https://doi.org/10.4081/dts.2012.e1

Vancouver

Ross LL, Robinson MD, Carosi G, Lazzarin A, Stellbrink H, Moyle G, et al. Impact of HIV subtype on response and resistance in antiretroviral-naïve adults comparing treatment with once daily versus twice daily ritonavir boosted fosamprenavir in combination with Abacavir/Lamivudine. Drugs and Therapy Studies. 2011. doi:10.4081/dts.2012.e1

BibTeX
@article{Ross2011,
  author = {Ross, Lisa L. and Robinson, Marjorie D. and Carosi, Giampiero and Lazzarin, Adriano and Stellbrink, Hans-Juergen and Moyle, Graeme and Givens, Naomi and Nichols, William G.},
  title = {Impact of HIV subtype on response and resistance in antiretroviral-naïve adults comparing treatment with once daily versus twice daily ritonavir boosted fosamprenavir in combination with Abacavir/Lamivudine},
  journal = {Drugs and Therapy Studies},
  year = {2011},
  doi = {10.4081/dts.2012.e1}
}
Kostenlos starten →